You are viewing the site in preview mode

Skip to main content
Fig. 1 | Advances in Rheumatology

Fig. 1

From: Risk factors for losing hepatitis B virus surface antibody in patients with HBV surface antigen negative/surface antibody positive serostatus receiving biologic disease-modifying anti-rheumatic drugs: a nested case-control study

Fig. 1

Case-control selection flow chart. DMARDs, disease-modifying anti-rheumatic drugs; HBV, hepatitis B virus; DNA, deoxyribonucleic acid; anti-HBs, HBV surface antibody; HBsAg, HBV surface-antigen; mIU, million International Units. aOne patient could serve as a control repeatedly during follow-up and control subjects could become cases during the study

Back to article page

Advances in Rheumatology

ISSN: 2523-3106